Qiagen

Premium
Qiagen this week launched a rat druggable genome siRNA set V1.0, which has been designed to enable researchers to knock down around 6,000 rat genes that correspond to human genes of potential therapeutic value.
 
The company designed the siRNAs using HP OnGuard siRNA design, which incorporates neural-network technology and a proprietary homology analysis method. Also available are subsets targeting 426 GPCR genes, 738 kinase genes, or 198 phosphatase genes, Qiagen said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.